Jiangsu Hengrui Pharmaceuticals CoSHSE:600276 +1.79%91 Interest Coverage is 5,758.90 as of Mar. 2026, which is 556% above its 10-year median of 878.36. GuruFocus rates SHSE:600276 with a GF Score™ of 91/100 and a GF Value™ of ¥60.54 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 684 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks better than 94.59% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Jiangsu Hengrui Pharmaceuticals Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥2,580 Mil. Jiangsu Hengrui Pharmaceuticals Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-0 Mil.
Jiangsu Hengrui Pharmaceuticals Co's interest coverage for the quarter that ended in Mar. 2026 was 5,758.90.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Jiangsu Hengrui Pharmaceuticals Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Interest Coverage or its related term are showing as below:
SHSE:600276'
s Interest Coverage Range Over the Past 10 Years
Min: 515.21 Med: 878.36 Max: 2364.63
Current: 2364.63
SHSE:600276's Interest Coverage is ranked better than 94.59% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs SHSE:600276: 2364.63
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Jiangsu Hengrui Pharmaceuticals Co Interest Coverage Related Terms
Jiangsu Hengrui Pharmaceuticals Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Jiangsu Hengrui Pharmaceuticals Co Interest Coverage Chart
SHSE:600276 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Interest Coverage falls into.
Jiangsu Hengrui Pharmaceuticals Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Interest Coverage of 5,758.90 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 556% above median its historical median of 878.36. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Interest Coverage has ranged from 515.21 to 2,364.63. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #37 out of 684 companies in the Drug Manufacturers industry, placing it in the top 5.4%.
Is Jiangsu Hengrui Pharmaceuticals Co's Interest Coverage too high?
Jiangsu Hengrui Pharmaceuticals Co's current Interest Coverage of 5,758.90 is 556% above median its 10-year median of 878.36. Over the past 10 years, this metric has ranged from a low of 515.21 to a high of 2,364.63. The Drug Manufacturers industry median Interest Coverage is 12.77. Jiangsu Hengrui Pharmaceuticals Co's value of 5,758.90 is 45014.8% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #37 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #37 out of 684 companies for Interest Coverage. This places Jiangsu Hengrui Pharmaceuticals Co in the top 5% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.77. Jiangsu Hengrui Pharmaceuticals Co's value of 5,758.90 is 45014.8% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Interest Coverage has ranged from 515.21 to 2,364.63 over the past decade. While the company's 10-year median is 878.36 vs. the industry median of 12.77, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Interest Coverage of 5,758.90 is 45014.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Interest Coverage is 5,758.90, which is 556% above median its own 10-year median of 878.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.54, compared to a current price of ¥54.45 — trading 10.1% below its estimated fair value. The current Interest Coverage is 5,758.90, which is 556% above median its 10-year median of 878.36 and 45014.8% above the Drug Manufacturers industry median of 12.77. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Interest Coverage is 5,758.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥54.45 is trading 10.1% below its estimated GF Value™ of ¥60.54.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
Interest Coverage: 5,758.90 (556% above median its 10-year median of 878.36)
GF Value™: ¥60.54 vs. price of ¥54.45 (10.1% below fair value)
Industry Position: 45014.8% above the Drug Manufacturers median (#37 of 684)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
91GF Score
Get the complete analysis for SHSE:600276
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
